Cargando…
Posaconazole-Induced Hypertension Due to Inhibition of 11β-Hydroxylase and 11β-Hydroxysteroid Dehydrogenase 2
We describe two cases of hypertension and hypokalemia due to mineralocorticoid excess caused by posaconazole treatment of coccidioidomycosis and rhinocerebral mucormycosis infections, respectively. Clinical laboratory evaluations, including a comprehensive analysis of blood and urine steroid profile...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Endocrine Society
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6608555/ https://www.ncbi.nlm.nih.gov/pubmed/31286100 http://dx.doi.org/10.1210/js.2019-00189 |
_version_ | 1783432189059268608 |
---|---|
author | Thompson, George R Beck, Katharina R Patt, Melanie Kratschmar, Denise V Odermatt, Alex |
author_facet | Thompson, George R Beck, Katharina R Patt, Melanie Kratschmar, Denise V Odermatt, Alex |
author_sort | Thompson, George R |
collection | PubMed |
description | We describe two cases of hypertension and hypokalemia due to mineralocorticoid excess caused by posaconazole treatment of coccidioidomycosis and rhinocerebral mucormycosis infections, respectively. Clinical laboratory evaluations, including a comprehensive analysis of blood and urine steroid profiles, revealed low renin and aldosterone and indicated as the underlying mechanism primarily a block of 11β-hydroxylase activity in patient 1, whereas patient 2 displayed weaker 11β-hydroxylase but more pronounced 11β-hydroxysteroid dehydrogenase 2 inhibition. The results show that both previously suggested mechanisms must be considered and emphasize significant interindividual differences in the contribution of each enzyme to the observed mineralocorticoid excess phenotype. The mineralocorticoid symptoms of patient 1 resolved after replacement of posaconazole therapy by isavoconazole, and posaconazole dosage de-escalation ameliorated the effects in patient 2. By providing a thorough analysis of the patients’ blood and urine steroid metabolites, this report adds further evidence for two individually pronounced mechanisms of posaconazole-induced hypertension and hypokalemia. The elucidation of the factors responsible for the individual phenotype warrants further research. |
format | Online Article Text |
id | pubmed-6608555 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Endocrine Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-66085552019-07-08 Posaconazole-Induced Hypertension Due to Inhibition of 11β-Hydroxylase and 11β-Hydroxysteroid Dehydrogenase 2 Thompson, George R Beck, Katharina R Patt, Melanie Kratschmar, Denise V Odermatt, Alex J Endocr Soc Case Report We describe two cases of hypertension and hypokalemia due to mineralocorticoid excess caused by posaconazole treatment of coccidioidomycosis and rhinocerebral mucormycosis infections, respectively. Clinical laboratory evaluations, including a comprehensive analysis of blood and urine steroid profiles, revealed low renin and aldosterone and indicated as the underlying mechanism primarily a block of 11β-hydroxylase activity in patient 1, whereas patient 2 displayed weaker 11β-hydroxylase but more pronounced 11β-hydroxysteroid dehydrogenase 2 inhibition. The results show that both previously suggested mechanisms must be considered and emphasize significant interindividual differences in the contribution of each enzyme to the observed mineralocorticoid excess phenotype. The mineralocorticoid symptoms of patient 1 resolved after replacement of posaconazole therapy by isavoconazole, and posaconazole dosage de-escalation ameliorated the effects in patient 2. By providing a thorough analysis of the patients’ blood and urine steroid metabolites, this report adds further evidence for two individually pronounced mechanisms of posaconazole-induced hypertension and hypokalemia. The elucidation of the factors responsible for the individual phenotype warrants further research. Endocrine Society 2019-06-06 /pmc/articles/PMC6608555/ /pubmed/31286100 http://dx.doi.org/10.1210/js.2019-00189 Text en Copyright © 2019 Endocrine Society https://creativecommons.org/licenses/by-nc-nd/4.0/ This article has been published under the terms of the Creative Commons Attribution Non-Commercial, No-Derivatives License (CC BY-NC-ND; https://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Case Report Thompson, George R Beck, Katharina R Patt, Melanie Kratschmar, Denise V Odermatt, Alex Posaconazole-Induced Hypertension Due to Inhibition of 11β-Hydroxylase and 11β-Hydroxysteroid Dehydrogenase 2 |
title | Posaconazole-Induced Hypertension Due to Inhibition of 11β-Hydroxylase and 11β-Hydroxysteroid Dehydrogenase 2 |
title_full | Posaconazole-Induced Hypertension Due to Inhibition of 11β-Hydroxylase and 11β-Hydroxysteroid Dehydrogenase 2 |
title_fullStr | Posaconazole-Induced Hypertension Due to Inhibition of 11β-Hydroxylase and 11β-Hydroxysteroid Dehydrogenase 2 |
title_full_unstemmed | Posaconazole-Induced Hypertension Due to Inhibition of 11β-Hydroxylase and 11β-Hydroxysteroid Dehydrogenase 2 |
title_short | Posaconazole-Induced Hypertension Due to Inhibition of 11β-Hydroxylase and 11β-Hydroxysteroid Dehydrogenase 2 |
title_sort | posaconazole-induced hypertension due to inhibition of 11β-hydroxylase and 11β-hydroxysteroid dehydrogenase 2 |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6608555/ https://www.ncbi.nlm.nih.gov/pubmed/31286100 http://dx.doi.org/10.1210/js.2019-00189 |
work_keys_str_mv | AT thompsongeorger posaconazoleinducedhypertensionduetoinhibitionof11bhydroxylaseand11bhydroxysteroiddehydrogenase2 AT beckkatharinar posaconazoleinducedhypertensionduetoinhibitionof11bhydroxylaseand11bhydroxysteroiddehydrogenase2 AT pattmelanie posaconazoleinducedhypertensionduetoinhibitionof11bhydroxylaseand11bhydroxysteroiddehydrogenase2 AT kratschmardenisev posaconazoleinducedhypertensionduetoinhibitionof11bhydroxylaseand11bhydroxysteroiddehydrogenase2 AT odermattalex posaconazoleinducedhypertensionduetoinhibitionof11bhydroxylaseand11bhydroxysteroiddehydrogenase2 |